CTLA4 and acute kidney injury: (59), it was proposed that the risk of AKI was higher with anti-CTLA-4 monotherapy than with anti-PD-1, for example, the risk of AKI grades 1-5 and 3-5 was higher with ipilimumab than with durvalumab.